Načítá se...
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
BACKGROUND: Bisphosphonates (BPs) including zoledronate (zol) have become standard care for bone metastases as they effectively inhibit tumor-induced osteolysis and associated pain. Several studies have also suggested that zol has direct anti-tumor activity. Systemic administration at high doses is...
Uloženo v:
| Vydáno v: | Cancer Cell Int |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6368819/ https://ncbi.nlm.nih.gov/pubmed/30787671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0745-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|